| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,188,470 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,765 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,188,470 |
|
|
| Total
Value |
$52,765 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-05-14 |
3,246,424 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
152 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 6 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-12 |
4 |
B |
$14.88 |
$208,047 |
D/D |
12,245 |
2,957,704 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-06 |
4 |
B |
$14.88 |
$4,762 |
D/D |
320 |
3,231,099 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-14 |
4 |
B |
$15.03 |
$2,255 |
D/D |
150 |
3,231,359 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-20 |
4 |
B |
$15.06 |
$1,657 |
D/D |
110 |
3,231,669 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-16 |
4 |
B |
$15.15 |
$1,742 |
D/D |
115 |
3,232,544 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-27 |
4 |
B |
$15.74 |
$7,870 |
D/D |
500 |
2,963,614 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-07-07 |
4 |
S |
$15.75 |
$28,161 |
D/D |
(1,788) |
876,815 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-10-06 |
4 |
S |
$15.87 |
$1,091,856 |
D/D |
(68,800) |
755,977 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-26 |
4 |
B |
$15.90 |
$7,950 |
D/D |
500 |
2,963,114 |
3.15 |
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2015-03-18 |
4 |
S |
$16.12 |
$22,375 |
D/D |
(1,388) |
7,285 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-10-03 |
4 |
S |
$16.14 |
$32,893 |
D/D |
(2,038) |
824,777 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-07 |
4 |
B |
$16.19 |
$1,781 |
D/D |
110 |
3,231,209 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-20 |
4 |
B |
$16.28 |
$16,280 |
D/D |
1,000 |
2,962,614 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-04-03 |
4 |
S |
$16.46 |
$29,891 |
D/D |
(1,816) |
878,603 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-26 |
4 |
B |
$16.50 |
$12,375 |
D/D |
750 |
3,230,779 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-05-16 |
4 |
B |
$17.03 |
$5,448 |
D/D |
320 |
3,228,649 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-05-31 |
4 |
B |
$17.28 |
$5,702 |
D/D |
330 |
3,229,179 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-07 |
4 |
B |
$17.41 |
$4,004 |
D/D |
230 |
3,229,409 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-05-24 |
4 |
B |
$17.49 |
$3,498 |
D/D |
200 |
3,228,849 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-08 |
4 |
B |
$17.53 |
$2,104 |
D/D |
120 |
3,229,529 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-21 |
4 |
B |
$17.88 |
$8,940 |
D/D |
500 |
3,230,029 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-13 |
4 |
B |
$18.10 |
$12,670 |
D/D |
700 |
2,958,404 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-18 |
4 |
B |
$18.49 |
$32,910 |
D/D |
1,700 |
2,961,414 |
3.23 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Accounting Officer |
• – – |
2006-03-29 |
4 |
S |
$18.78 |
$658,376 |
D/D |
(35,000) |
14,991 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-19 |
4 |
B |
$18.95 |
$3,790 |
D/D |
200 |
2,961,614 |
3.15 |
- |
|
152 Records found
|
|
Page 6 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
